Accelerating Medical Treatments for Serious Mental Illness
- Executive Order Number
- 14401
- President
- Donald Trump
- Signed
- April 18, 2026
- Published
- April 22, 2026
- Source
- Federal Register
- Original Document
- https://www.govinfo.gov/content/pkg/FR-2026-04-22/pdf/2026-07907.pdf
AI-Generated Summary
Summary of Executive Order on Psychedelic Drugs for Mental Health
Purpose
The executive order aims to address the crisis of suicide and serious mental illnesses (affecting over 14 million U.S. adults, with elevated rates among veterans) by accelerating research, development, and access to promising psychedelic drugs (e.g., ibogaine compounds). It emphasizes innovative therapies beyond standard treatments, building on FDA Breakthrough Therapy designations and clinical trial progress, to reverse rising suicide rates and improve outcomes for treatment-resistant patients.
Key Actions or Directives
- FDA Prioritization (Sec. 2): Issue Commissioner's National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy status; establish pathways under the Right to Try Act for patient access, including Schedule I handling authorizations for physicians/researchers.
- HHS Funding (Sec. 3): Allocate at least $50 million from existing funds via ARPA-H to support state programs advancing psychedelics for mental illnesses, including federal funding, technical assistance, and data sharing.
- Interagency Collaboration (Sec. 4): HHS and FDA partner with VA and private sector (consistent with privacy laws) to boost clinical trials, data sharing, and real-world evidence for psychedelics; execute data-sharing memoranda to expedite FDA approvals.
- Rescheduling Review (Sec. 5): Attorney General, consulting HHS, initiate and complete reviews for Schedule I products completing Phase 3 trials, enabling swift rescheduling if approved by FDA.
Significant Changes to Policy or Law
- Prioritizes psychedelic drugs in FDA processes via vouchers and Right to Try expansions, despite Schedule I status under the Controlled Substances Act.
- Directs proactive rescheduling reviews post-Phase 3 trials, accelerating potential shifts from Schedule I.
- Allocates specific funding for state-federal psychedelic initiatives and mandates data-sharing across agencies, enhancing efficiency without new legislation.
Potential Impacts
- Government Agencies: Increased workload and coordination for FDA, HHS, DEA, VA; faster drug reviews and approvals.
- Citizens: Expanded access to experimental psychedelics for treatment-resistant mental illnesses, potentially reducing suicides (targeting veterans disproportionately affected).
- International Relations: Minimal direct impact, though could influence global psychedelic research norms via U.S. leadership in approvals.
Main Stakeholders Affected
- Patients: Adults with serious mental illnesses (e.g., major depression, substance use disorders), veterans (suicide rate >2x non-veterans).
- Government Entities: FDA, HHS (ARPA-H), DEA, VA, Attorney General.
- Other: State governments, private sector (pharma, researchers, clinical trial participants), treating physicians.
Notable Legal, Constitutional, or Political Implications
- Legal: Operates within existing frameworks (e.g., Right to Try Act, FDA approval statutes, CSA waivers); includes standard non-impairment clause (Sec. 6) and no enforceable rights created.
- Constitutional: Exercises President's Article II authority over executive agencies; subject to appropriations and applicable law.
- Political: Signals policy shift toward psychedelic therapies, crediting prior administration progress while critiquing recent setbacks; promotes innovation without mandating approvals or overriding safety standards.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.